Don’t Jump to Topical Vtama or Zoryve for Psoriasis

October 2022

Vtama (tapinarof) and Zoryve (roflumilast) will be two new once-daily Rx creams for psoriasis.

Both will be touted as steroid-free options that are safe for long-term use, even on thin-skinned areas (face, groin, etc).

But they each reduce inflammation differently.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

COVID-19 Be Ready With Answers About Bivalent COVID-19 Boosters
Allergic Reactions Sort Through Specifics of Sulfa Allergies
NSAIDs Consider Kidney Risks Before Using an NSAID
Diabetes Expect Buzz About CGM With New FreeStyle Libre 3
Heart Failure Steer Away From Meds That Can Exacerbate Heart Failure
Immunizations Prevent Errors With COVID-19 Boosters and Flu Vaccinations
Psoriasis Don’t Jump to Topical Vtama or Zoryve for Psoriasis
Gastroenterology Follow a Stepwise Approach to Managing Gastroparesis
Hypotension Save Meds as a Last Resort for Orthostatic Hypotension
Medicare Navigate Medicare Part D Plan Changes for 2023
Antiplatelets Know How to Manage Antiplatelets Around Surgery
Diuretics Guide Fluid De-Resuscitation in the ICU
Hematology & Oncology Act Fast When Treating Febrile Neutropenia